TheraRadar
← Back
Data updated: Mar 29, 2026

HONG KONG

RespiratoryDermatologyOncology
Pharma

HONG KONG is a pharmaceutical company focused on Respiratory, Dermatology, Oncology. Key products include XENLETA.

2004
Since
3
Drugs
-
Trials
12
Approved (2yr)

Key Drugs

XENLETA
lefamulin acetate
· 2019

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

METHYLPREDNISOLONE ACETATE 2026-01-26
METHYLPREDNISOLONE ACETATE 2026-01-20
Labeling
METHYLPREDNISOLONE ACETATE 2026-01-20
Labeling
METHYLPREDNISOLONE ACETATE 2025-04-16
MEDROXYPROGESTERONE ACETATE 2025-03-13
Labeling
METHYLPREDNISOLONE ACETATE 2025-02-12
Labeling
METHYLPREDNISOLONE ACETATE 2025-02-12
Labeling
METHYLPREDNISOLONE ACETATE 2024-10-15
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 33%
1 drugs Phase 2: 2 Phase 1: 1
Dermatology 18%
1 drugs
Oncology 18%
0 drugs Phase 1: 6
Immunology 18%
0 drugs Phase 2: 3
Gastroenterology 12%
0 drugs Phase 2: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Dermatology, Immunology, Gastroenterology
Novartis big-pharma
Oncology, Immunology, Respiratory
Gilead Sciences biotech
Oncology, Immunology, Gastroenterology, Respiratory
MALLINCKRODT specialty
Gastroenterology, Dermatology, Immunology, Respiratory
GSK big-pharma
Respiratory, Oncology, Immunology